A Study to Assess the Safety and Efficacy of Lenvatinib as First-line Treatment in Participants With Unresectable HCC
Clinical trial NCT04297254 · COMPLETED
Trial details
- NCT number
- NCT04297254
- Sponsor
- Eisai Pharmaceuticals India Pvt. Ltd
- Status
- COMPLETED
- Phase
- Phase 4
- Study type
- INTERVENTIONAL
- Start date
- 2021-02-04
- Primary completion
- 2023-07-31
- Enrollment
- 50
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.